ArticleFrontiers in immunology2026

Dual-targeting CD73/PD-L1 bifunctional inhibitor: a promising cancer immunotherapy strategy.

Jing-Jing Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.